Anchor Therapeutics collaborates with Kyowa Hakko Kirin for its pepducin technology

Anchor Therapeutics has entered into a collaborative agreement with Kyowa Hakko Kirin to utilize Anchor’s proprietary pepducin technology to advance KHK’s internal G protein-coupled receptor drug discovery portfolio. This agreement takes advantage of Anchor’s expanded business strategy to offer its pepducin technology for use as in vitro and in vivo research tools, in addition to [...]The post Anchor Therapeutics collaborates with Kyowa Hakko Kirin for its pepducin technology appeared firs..

Original Article: Anchor Therapeutics collaborates with Kyowa Hakko Kirin for its pepducin technology

More From BioPortfolio on "Anchor Therapeutics collaborates with Kyowa Hakko Kirin for its pepducin technology"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications